AbCellera Biologics (NASDAQ:ABCL) vs. Neurogene (NASDAQ:NGNE) Financial Survey

Neurogene (NASDAQ:NGNE) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Volatility & Risk

Neurogene has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Valuation and Earnings

This table compares Neurogene and AbCellera Biologics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$925,000.00	380.61	-$36.32 million	N/A	N/A
AbCellera Biologics	$32.96 million	27.06	-$146.40 million	($0.61)	-4.95

Neurogene has higher earnings, but lower revenue than AbCellera Biologics.

Analyst Ratings

This is a summary of current ratings and price targets for Neurogene and AbCellera Biologics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	0	0	8	1	3.11
AbCellera Biologics	0	1	2	0	2.67

Neurogene presently has a consensus target price of $60.83, indicating a potential upside of 156.68%. AbCellera Biologics has a consensus target price of $8.67, indicating a potential upside of 186.98%. Given AbCellera Biologics’ higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than Neurogene.

Profitability

This table compares Neurogene and AbCellera Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-32.81%	-27.96%
AbCellera Biologics	-533.32%	-15.73%	-12.22%

Insider and Institutional Ownership

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 9.9% of Neurogene shares are owned by insiders. Comparatively, 28.0% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Neurogene beats AbCellera Biologics on 7 of the 13 factors compared between the two stocks.

About Neurogene

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

About AbCellera Biologics

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.